NT5C1A
Cytosolic 5'-nucleotidase 1A
Also known as: 5NT1A_HUMAN, CN-I, CN-IA, CN1, CN1A, MGC119199, MGC119201
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BXI3
- Gene
- NT5C1A
- Ensembl
- ENSG00000116981
- Chromosome
- 1
- Canonical length
- 368 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted intracellular proteins
OverviewNCBI Gene
Cytosolic nucleotidases, such as NT5C1A, dephosphorylate nucleoside monophosphates (Hunsucker et al., 2001 [PubMed 11133996]).[supplied by OMIM, Mar 2008]
Canonical amino-acid sequenceUniProt
368 residues, UniProt reviewed canonical sequence.
>Q9BXI3|NT5C1A
1 MEPGQPREPQ EPREPGPGAE TAAAPVWEEA KIFYDNLAPK KKPKSPKPQN AVTIAVSSRA
61 LFRMDEEQQI YTEQGVEEYV RYQLEHENEP FSPGPAFPFV KALEAVNRRL RELYPDSEDV
121 FDIVLMTNNH AQVGVRLINS INHYDLFIER FCMTGGNSPI CYLKAYHTNL YLSADAEKVR
181 EAIDEGIAAA TIFSPSRDVV VSQSQLRVAF DGDAVLFSDE SERIVKAHGL DRFFEHEKAH
241 ENKPLAQGPL KGFLEALGRL QKKFYSKGLR LECPIRTYLV TARSAASSGA RALKTLRSWG
301 LETDEALFLA GAPKGPLLEK IRPHIFFDDQ MFHVAGAQEM GTVAAHVPYG VAQTPRRTAP
361 AKQAPSAQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NT5C1A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.3
- Highest tissue expression
- 73 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 73 nTPM
- tongue: 29 nTPM
- cerebellum: 8.1 nTPM
- heart muscle: 6.5 nTPM
- pancreas: 2.8 nTPM
- cerebral cortex: 2.6 nTPM
Single-cell type
- adrenal medulla cells: 32 nCPM
- myonuclei: 27 nCPM
- cardiomyocytes: 13 nCPM
- retinal amacrine cells: 8.1 nCPM
- hepatic stellate cells: 6.5 nCPM
- vascular smooth muscle cells: 5 nCPM
Immune cell
- basophil: 0.1 nTPM
- neutrophil: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- cerebral cortex: 14 nTPM
- cerebellum: 14 nTPM
- midbrain: 12 nTPM
- pons: 9.6 nTPM
- hypothalamus: 9.5 nTPM
- thalamus: 9.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about NT5C1A.
Disease | AutoantibodyPubMed
Conditions in which antibodies against NT5C1A are reported. Each links to that disease's full target list.
Showing 5 of 7 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for NT5C1A from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
43 publications
- Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis.
2013 · Ann Neurol · RCR 6.6 · 200 citations - Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.
2016 · Ann Rheum Dis · RCR 5.3 · 111 citations - Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.
2019 · Ann Rheum Dis · RCR 4.9 · 99 citations - Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues.
2024 · Front Immunol · RCR 3.9 · 17 citations - Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.
2016 · Arthritis Care Res (Hoboken) · RCR 3.8 · 83 citations
Show 20 more of 43 total
- Narrative review of autoantibodies in idiopathic inflammatory myopathies.
2023 · Ann Transl Med · RCR 3.1 · 17 citations - Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis.
2017 · Ann Neurol · RCR 2.8 · 64 citations - Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis.
2019 · Front Immunol · RCR 2.3 · 43 citations - Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis.
2022 · Clin Exp Rheumatol · RCR 2.2 · 21 citations - Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility.
2014 · Muscle Nerve · RCR 2.1 · 52 citations - Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis.
2021 · Cells · RCR 2 · 24 citations - Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients.
2017 · Neurology · RCR 2 · 40 citations - Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
2018 · Front Immunol · RCR 1.8 · 35 citations - Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies.
2021 · Ann Clin Transl Neurol · RCR 1.8 · 22 citations - Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients.
2022 · Rheumatology (Oxford) · RCR 1.8 · 15 citations - Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis.
2021 · Muscle Nerve · RCR 1.7 · 21 citations - Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.
2018 · Ann Rheum Dis · RCR 1.7 · 29 citations - Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts.
2017 · Clin Chim Acta · RCR 1.5 · 28 citations - Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches.
2015 · J Clin Neurosci · RCR 1.4 · 35 citations - Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis.
2023 · J Neurol Neurosurg Psychiatry · RCR 1.4 · 10 citations - Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.
2016 · Auto Immun Highlights · RCR 1.2 · 25 citations - Diagnostic Accuracy of Anti-CN1A on the Diagnosis of Inclusion Body Myositis. A Hierarchical Bivariate and Bayesian Meta-analysis.
2021 · J Clin Neuromuscul Dis · RCR 1.2 · 16 citations - Myositis-related autoantibody profile and clinical characteristics stratified by anti-cytosolic 5'-nucleotidase 1A status in connective tissue diseases.
2023 · Muscle Nerve · RCR 1.1 · 7 citations - Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center.
2018 · Neuromuscul Disord · RCR 1.1 · 21 citations - Clinical significance of anti-NT5c1A autoantibody in Korean patients with inflammatory myopathies.
2023 · PLoS One · RCR 1.1 · 7 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.96
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.87
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adenosine metabolic process
- allantoin metabolic process
- AMP catabolic process
- dAMP catabolic process
- dGMP catabolic process
- IMP catabolic process
- nucleoside metabolic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NT5C1A as an antibody target. Whether an autoantibody or antibody against NT5C1A could matter depends on whether native NT5C1A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NT5C1A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NT5C1A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...